Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Orphanet Journal of Rare Diseases

Figure 6

From: Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis

Figure 6

Antibacterial efficacy of cysteamine and tobramycin on P. aeruginosa incubated under nutrient-limiting and Nutrient replete conditions. The MIC100 of P. aeruginosa PAO1, P. aeruginosa NH57388A and P. aeruginosa NH57388B were determined according to standard CLSI conditions for – A) nutrient replete media (MH broth), whereas – B) M9 minimal medium was substituted for MH broth to provide nutrient-limiting conditions. The graphs (A & B) show data for P. aeruginosa PAO1. The table shows the mean MIC of triplicate samples from triplicate experiments. Error bars represent the Standard Error of the Mean. P. aeruginosa NH57388A is a mucoid strain. P. aeruginosa NH57388B is a non-mucoid strain. * - P. aeruginosa NH57388B is tobramycin resistant.

Back to article page